Bill
Bill > HR7556
US HR7556
US HR7556To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research.
summary
Introduced
07/09/2020
07/09/2020
In Committee
07/09/2020
07/09/2020
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
To amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. This bill allows certain small businesses whose gross receipts do not exceed $1 million a refundable portion of the tax credit for increasing research activities if such businesses are engaging in specified medical research. It defines specified medical research as any qualified research with respect to qualified countermeasures. A qualified countermeasure is a drug, biological product, or device that is determined to be a priority (1) to diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; (2) to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device; or (3) is a product or technology intended to enhance the use or effect of a drug, biological product, or device.
AI Summary
This bill allows certain small businesses whose gross receipts do not exceed $1 million to claim a refundable portion of the tax credit for increasing research activities if they are engaging in specified medical research. Specified medical research is defined as any qualified research with respect to qualified countermeasures, which are drugs, biological products, or devices determined to be a priority to diagnose, mitigate, prevent, or treat harm from biological agents, toxins, chemicals, radiological, or nuclear agents that may cause a public health emergency affecting national security, or to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device. The bill also provides for the election and regulation of this refundable tax credit provision.
Committee Categories
Budget and Finance
Sponsors (1)
Last Action
Referred to the House Committee on Ways and Means. (on 07/09/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/7556/all-info |
| BillText | https://www.congress.gov/116/bills/hr7556/BILLS-116hr7556ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr7556/BILLS-116hr7556ih.pdf.pdf |
Loading...